BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CNS Disease Analysis: Parkinson’s Disease

December 10, 2020

Parkinson’s disease is a chronic disorder characterized by movement abnormalities and other non-motor symptoms, such as dementia, depression, visual hallucinations, and autonomic dysfunction. Although not fatal, there is currently no cure for the disease, and its chronicity is associated with significant morbidity and disability.

The loss of dopaminergic neurons and the accumulation of intracellular inclusions, known as Lewy bodies, are the pathological hallmarks of Parkinson’s disease. Dopamine neurotransmission to the basal ganglia in the brain is reduced by the death of dopaminergic neurons in the substantia nigra, thus causing a loss of muscle control. While the progressive loss of dopaminergic neurons occurs in normal aging, symptomatic Parkinson’s disease patients are estimated to lose 70–80% of these cells.

Parkinson’s disease is the second most common neurodegenerative disorder in the elderly, after Alzheimer’s disease. The average age of onset is approximately 60 years, after which the risk of disease increases significantly. As global demographic shifts continue to increase the relative proportion of elderly populations, the social and economic burden associated with Parkinson’s disease is likely to increase considerably.

This Datamonitor Healthcare report contains a Disease Analysis module.
 

Indications Covered: Parkinson's Disease (PD)
Back to the top Back to the top